181 related articles for article (PubMed ID: 38646883)
1. GS-441524-Diphosphate-Ribose Derivatives as Nanomolar Binders and Fluorescence Polarization Tracers for SARS-CoV-2 and Other Viral Macrodomains.
Peng K; Wallace SD; Bagde SR; Shang J; Anmangandla A; Jana S; Fromme JC; Lin H
ACS Chem Biol; 2024 May; 19(5):1093-1105. PubMed ID: 38646883
[TBL] [Abstract][Full Text] [Related]
2. The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase.
Alhammad YMO; Kashipathy MM; Roy A; Gagné JP; McDonald P; Gao P; Nonfoux L; Battaile KP; Johnson DK; Holmstrom ED; Poirier GG; Lovell S; Fehr AR
J Virol; 2021 Jan; 95(3):. PubMed ID: 33158944
[TBL] [Abstract][Full Text] [Related]
3. A Fluorescence Polarization Assay for Macrodomains Facilitates the Identification of Potent Inhibitors of the SARS-CoV-2 Macrodomain.
Anmangandla A; Jana S; Peng K; Wallace SD; Bagde SR; Drown BS; Xu J; Hergenrother PJ; Fromme JC; Lin H
ACS Chem Biol; 2023 May; 18(5):1200-1207. PubMed ID: 37126856
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain.
Sherrill LM; Joya EE; Walker A; Roy A; Alhammad YM; Atobatele M; Wazir S; Abbas G; Keane P; Zhuo J; Leung AKL; Johnson DK; Lehtiö L; Fehr AR; Ferraris D
Bioorg Med Chem; 2022 Aug; 67():116788. PubMed ID: 35597097
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
Jung LS; Gund TM; Narayan M
Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
[TBL] [Abstract][Full Text] [Related]
6. Molecular insight into the specific binding of ADP-ribose to the nsP3 macro domains of chikungunya and Venezuelan equine encephalitis viruses: molecular dynamics simulations and free energy calculations.
Rungrotmongkol T; Nunthaboot N; Malaisree M; Kaiyawet N; Yotmanee P; Meeprasert A; Hannongbua S
J Mol Graph Model; 2010 Nov; 29(3):347-53. PubMed ID: 21036084
[TBL] [Abstract][Full Text] [Related]
7. The search for inhibitors of macrodomains for targeting the readers and erasers of mono-ADP-ribosylation.
Fu W; Yao H; Bütepage M; Zhao Q; Lüscher B; Li J
Drug Discov Today; 2021 Nov; 26(11):2547-2558. PubMed ID: 34023495
[TBL] [Abstract][Full Text] [Related]
8. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
9. Macrodomain Mac1 of SARS-CoV-2 Nonstructural Protein 3 Hydrolyzes Diverse ADP-ribosylated Substrates.
Chea C; Lee DY; Kato J; Ishiwata-Endo H; Moss J
bioRxiv; 2023 Feb; ():. PubMed ID: 36945431
[TBL] [Abstract][Full Text] [Related]
10. The SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase.
Alhammad YMO; Kashipathy MM; Roy A; Gagné JP; McDonald P; Gao P; Nonfoux L; Battaile KP; Johnson DK; Holmstrom ED; Poirier GG; Lovell S; Fehr AR
bioRxiv; 2020 Oct; ():. PubMed ID: 32511412
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Screening and Quantum Mechanics for Identifying Potent Inhibitors Against Mac1 Domain of SARS-CoV-2 Nsp3.
Selvaraj C; Dinesh DC; Panwar U; Boura E; Singh SK
IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1262-1270. PubMed ID: 33306471
[TBL] [Abstract][Full Text] [Related]
12. NMR study of macro domains (MDs) from betacoronavirus: backbone resonance assignments of SARS-CoV and MERS-CoV MDs in the free and the ADPr-bound state.
Tsika AC; Fourkiotis NK; Charalampous P; Gallo A; Spyroulias GA
Biomol NMR Assign; 2022 Apr; 16(1):9-16. PubMed ID: 34686999
[TBL] [Abstract][Full Text] [Related]
13. Viral macrodomains: a structural and evolutionary assessment of the pharmacological potential.
Rack JGM; Zorzini V; Zhu Z; Schuller M; Ahel D; Ahel I
Open Biol; 2020 Nov; 10(11):200237. PubMed ID: 33202171
[TBL] [Abstract][Full Text] [Related]
14.
Xie S; Cao S; Wu J; Xie Z; Liu YT; Fu W; Zhao Q; Liu L; Yang L; Li J
J Biomol Struct Dyn; 2024 Jul; 42(10):5229-5237. PubMed ID: 37349935
[TBL] [Abstract][Full Text] [Related]
15. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
Roy A; Alhammad YM; McDonald P; Johnson DK; Zhuo J; Wazir S; Ferraris D; Lehtiö L; Leung AKL; Fehr AR
Antiviral Res; 2022 Jul; 203():105344. PubMed ID: 35598780
[TBL] [Abstract][Full Text] [Related]
16. The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection.
Fehr AR; Channappanavar R; Jankevicius G; Fett C; Zhao J; Athmer J; Meyerholz DK; Ahel I; Perlman S
mBio; 2016 Dec; 7(6):. PubMed ID: 27965448
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain.
Dasovich M; Zhuo J; Goodman JA; Thomas A; McPherson RL; Jayabalan AK; Busa VF; Cheng SJ; Murphy BA; Redinger KR; Alhammad YMO; Fehr AR; Tsukamoto T; Slusher BS; Bosch J; Wei H; Leung AKL
ACS Chem Biol; 2022 Jan; 17(1):17-23. PubMed ID: 34904435
[TBL] [Abstract][Full Text] [Related]
20. ADP-ribosylhydrolases: from DNA damage repair to COVID-19.
Yu L; Liu X; Yu X
J Zhejiang Univ Sci B; 2021 Jan; 22(1):21-30. PubMed ID: 33448184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
